Microbot Medical (MBOT) – Research Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Microbot Medical (NASDAQ: MBOT) in the last few weeks:

• 10/24/2026 – Microbot Medical was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/23/2026 – Microbot Medical was given a new $2.50 price target by UBS Group.
• 10/23/2026 – Microbot Medical is now covered by Citigroup. They set a “market outperform” rating on the stock.
• 10/23/2026 – Microbot Medical is now covered by Citizens Jmp. They set a “market outperform” rating and a $2.50 price target on the stock.
• 10/21/2026 – Microbot Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
• 10/2/2026 – Microbot Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/19/2026 – Microbot Medical was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/11/2026 – Microbot Medical is now covered by B. Riley Financial. They set a “buy” rating and a $4.00 price target on the stock.
• 9/5/2026 – Microbot Medical was downgraded by Wall Street Zen from “sell” to “strong sell”.

Microbot Medical Stock Performance

Shares of MBOT traded down $0.05 during midday trading on Monday, hitting $1.04. The company had a trading volume of 1,079,171 shares, compared to its average volume of 1,311,033. The company’s 50-day simple moving average is $1.24 and its 200-day simple moving average is $1.84. Microbot Medical Inc. has a 1 year low of $0.93 and a 1 year high of $2.85. The firm has a market capitalization of $69.86 million, a P/E ratio of -4.33 and a beta of 1.07.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. Equities analysts predict that Microbot Medical Inc. will post -0.30 earnings per share for the current fiscal year.

Microbot Medical Inc (NASDAQ: MBOT) is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians’ exposure to radiation.

The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.